Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics and Concurrent PIPE Investment
New York – June 23, 2023 – Cooley advised Aeglea BioTherapeutics, a clinical-stage biotechnology company, on its acquisition of Spyre Therapeutics and concurrent private investment. Lawyers Bill Sorabella, Matthew Silverman, Maya Rahwanji, Courtney Tygesson and Richard Segal led the Cooley team advising Aeglea.
The acquisition of Spyre had an implied value of approximately $110 million, payable in shares of Aeglea, excluding the additional proceeds from the concurrent oversubscribed $210 million private investment in public equity (PIPE).
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.